In some people with non-Hodgkin lymphoma (NHL), treating a single tumor with a mix of cancer therapies can help to shrink, or eliminate, tumors in other parts of the body, findings from […]
CC Staff
Some Children with Liver Cancer May Need Less Chemotherapy, Study Suggests
Some children with liver cancer may need less chemotherapy than is typically used to treat the disease, according to results from a phase 3 clinical trial. The study, led by the NCI-supported […]
Prescribing Exercise as Cancer Treatment: A Conversation with Dr. Kathryn Schmitz
On October 16, 2019, an expert panel convened by the American College of Sports Medicine (ACSM) released updated guidance and recommendations on the role of physical activity and exercise in cancer prevention and […]
For HPV-Positive Women, Test Can Guide Cervical Cancer Screening Follow-Up
A new test can help to improve the clinical management of women who screen positive for human papillomavirus (HPV) infection in routine cervical cancer screening, an NCI-led study has shown. The test, called p16/Ki-67 […]
Genomic Test Helps Identify Thyroid Nodules That Don’t Require Surgery
A new study has found that a test that measures genomic changes in tissue samples taken from the thyroid can help identify which patients likely need diagnostic surgery for thyroid cancer and which do […]
A Rapidly Emerging Field of Cancer Treatment
The human body normally runs like a well-oiled machine. It is able to activate muscles and run repairs without a conscious thought. One of the truly fascinating components of the human body […]
Could a Vaccine Prevent Colorectal Cancer in People with Lynch Syndrome?
Researchers have taken the first steps toward developing a vaccine to prevent cancer in people with Lynch syndrome, an inherited condition that elevates a person’s risk of colorectal, endometrial, and other types of cancer. The scientists, led by Steven […]
Overcoming a Cancer Nemesis? KRAS Inhibitor Shows Promise in Early Trial
After decades of trying, in 2013 scientists developed a breakthrough drug that targets one of the most hard-to-hit cancer-related proteins, called KRAS. Now results on the first KRAS inhibitor to enter a clinical […]